Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes

Authors

Charles M Bowen
Krishna M Sinha
Eduardo Vilar

Publication Date

5-1-2024

Journal

Colorectal Cancer Surgery

DOI

10.1055/s-0043-1770383

PMID

38606044

PMCID

PMC11006444

PubMedCentral® Posted Date

7-31-2023

PubMedCentral® Full Text Version

Post-print

Abstract

The coming of age for cancer treatment has experienced exponential growth in the last decade with the addition of immunotherapy as the fourth pillar to the fundamentals of cancer treatment-chemotherapy, surgery, and radiation-taking oncology to an astounding new frontier. In this time, rapid developments in computational biology coupled with immunology have led to the exploration of priming the host immune system through vaccination to prevent and treat certain subsets of cancer such as melanoma and hereditary colorectal cancer. By targeting the immune system through tumor-specific antigens-namely, neoantigens (neoAgs)-the future of cancer prevention may lie within arm's reach by employing neoAg vaccines as an immune-preventive modality for hereditary cancer syndromes like Lynch syndrome. In this review, we discuss the history, current trends, utilization, and future direction of neoAg-based vaccines in the setting of hereditary colorectal cancer.

Keywords

neoantigen, Lynch syndrome, cancer vaccine, cancer prevention, hereditary colorectal cancer

Published Open-Access

yes

Recommended Citation

Charles M Bowen, Krishna M Sinha, and Eduardo Vilar, "Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes" (2024). Faculty, Staff and Student Publications. 5076.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5076